解放军医学院学报2017，Vol.38Issue(6)：505-508,4.DOI:10.3969/j.issn.2095-5227.2017.06.004
小剂量地西他滨序贯减量CAG方案治疗中高危骨髓增生异常综合征疗效观察
Clinical outcome of ultra low-dose decitabine combined with reduced-intensity CAG therapeutic regimen on intermediate or high risk myelodysplastic syndrome
摘要
Abstract
Objective To observe the clinical outcome and safety of ultra low-dose of decitabine (DAC) combined with reduced-intensity CAG (aclacinomycin, cytarabine, granulocyte colony stimulating factor) therapeutic regimen on intermediate or high risk myelodysplastic syndrome (MDS). Methods Total of 30 patients treated by ultra low-dose DAC combined with reduced-intensity CAG therapeutic regimen in our center from Apr. 2015 to Oct. 2016 were included in this study, and the clinical outcome, adverse reactions, and survival data were recorded. Results Of all the patients, complete remission (CR) rate was 53% (16 cases), partial remission rate (PR) was 17% (5 cases), hematological improvement (HI) rate was 10% (3 cases), total failure (TF) was 20% (6 cases) and overall response rate (ORR) was 80%. Infection was the main adverse event caused by DAC and occurred in 15 patients (50%), with 2 of them severely infected. The median survival time was 11 months (2-18 months) with 24 survived and 4 died. Conclusion Ultra low-dose DAC combined with reduced-intensity CAG therapeutic regimen is effective and safe on intermediate or high risk MDS with lower rate of severe infection and hematological toxicities.关键词
骨髓增生异常综合征/地西他滨/低剂量/CAG方案Key words
myelodysplastic syndrome/decitabine/low-dose/CAG regimen分类
医药卫生引用本文复制引用
吴亚妹,张雅茜,王丽,吴晓雄,曹永彬,李晓红,徐丽昕,闫蓓,李松威,汪海涛,高亚会,张甜甜..小剂量地西他滨序贯减量CAG方案治疗中高危骨髓增生异常综合征疗效观察[J].解放军医学院学报,2017,38(6):505-508,4.基金项目
部委级资助项目 （）
全军医学科技青年培育项目 (13QNP 179 （）
16QNO138) Supported by the Medical Science and Technique Training Foundation for Youths of theChinesePeople'sLiberationArmy (13QNP179 （）
16QNO138) （）
